Te­va calls off CGRP drug dis­cov­ery and de­vel­op­ment pact, re­turns pre­clin­i­cal as­set to So­sei

A strug­gling Te­va has pulled out of a CGRP mi­graine drug dis­cov­ery and de­vel­op­ment pact with the G pro­tein cou­pled re­cep­tor ex­perts at So­sei, just as the lead can­di­date looks ready to start clin­i­cal de­vel­op­ment.

That re­turns the world­wide rights to HTL0022562 to So­sei’s UK sub­sidiary Hep­tares Ther­a­peu­tics, which plans to re­view the pro­grams be­fore up­dat­ing the time frame of the drug’s en­try in­to Phase I clin­i­cal tri­als, orig­i­nal­ly ex­pect­ed in late 2018. Te­va — which at­trib­uted the move to­day to its on­go­ing repri­or­i­ti­za­tion ef­fort on the pipeline — is al­so hand­ing over all the pre­clin­i­cal da­ta it gen­er­at­ed, as well as all li­cens­ing rights re­lat­ing to any CGRP an­tag­o­nist pro­grams cov­ered by the ini­tial agree­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.